# A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

> **NCT05284032** · EARLY_PHASE1 · TERMINATED · sponsor: **Firas El Chaer, MD** · enrollment: 3 (actual)

## Conditions studied

- Platelet Refractoriness
- Hematologic Malignancy

## Interventions

- **DRUG:** isatuximab 10 mg/kg

## Key facts

- **NCT ID:** NCT05284032
- **Lead sponsor:** Firas El Chaer, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-29
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05284032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05284032, "A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05284032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*